Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 mass balance and pharmacokinetics study of [14C]-GBT021601 in healthy participants
NL-OMON53865Phase 1Active, not recruiting
- Sponsor
- Global Blood Therapeutics, Inc.
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of osivelotor in sickle cell disease (SCD) and sickle cell anemia (SCA), sponsored by Global Blood Therapeutics, Inc. Primary endpoints: Whole blood and plasma total radioactivity concentrations, Mass balance and excretion and 1 more. Started Nov 2022; status: active, not recruiting.
02
Drugs
osivelotor
03
Conditions
sickle cell disease (SCD)sickle cell anemia (SCA)
Beyond the preview
Go deeper on NL-OMON53865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53865.